Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

  • Technology appraisal guidance
  • TA1152
  • Published: 

Tools and resources

Tools and resources to help you put the guidance into practice.

Summary versions

Resource impact

Guidance into practice